Clinical trial · Observational
Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery
Impact of Baumann Skin Type on Wound Healing and Scar Formation Following Facial Skin Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery. The main questions it aims to answer are: How does skin type affect the quality of wound healing after facial surgery? How does skin type affect the formation of hypertrophic scars after facial surgery? Researchers will compare groups of patients with different skin types (classified by the Baumann Skin Type) to see if there are significant differences in their healing outcomes and scar characteristics. Participants in this study will: Receive standard facial dermatologic surgery as part of their clinical care. Have their skin type assessed preoperatively. Undergo scheduled postoperative follow-up assessments at 7 and 90 days to evaluate wound healing and scar development using standardized scales.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cyst | — | UNRESOLVED | — |
| Lipoma | Lipoma | ONTOLOGY_EXACT | 0.98 |
| Nevus | Nevus | ONTOLOGY_EXACT | 0.98 |
| Scar | — | UNRESOLVED | — |
| Seborrheic Keratosis (SK) | Seborrheic Keratosis | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Oily Skin
- description
- classified as having oily skin according to the Baumann questionnaire
- label
- Dry Skin
- description
- classified as having dry skin according to the Baumann questionnaire
Primary outcomes (2)
- measure
- Patient and Observer Scar Assessment Scale version 2.0 (POSAS 2.0)
- timeFrame
- 3-month follow-up
- description
- This scale comprises two separate subscales: the Observer Scar Assessment Scale (completed by the clinician) and the Patient Scar Assessment Scale (completed by the participant). The Observer Scale evaluates six items (vascularity, pigmentation, thickness, relief, pliability, and surface area) on a scale from 1 ("like normal skin") to 10 ("the worst scar imaginable"), with a total score ranging from 6 (best) to 60 (worst). The Patient Scale evaluates six items (pain, itching, color, stiffness, thickness, and irregularity) on a scale from 1 ("no, not at all") to 10 ("yes, very much"), with a total score also ranging from 6 (best) to 60 (worst). For both subscales, a higher score indicates a worse scar quality.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Aged between 14 and 60 years. * Clinically and postoperatively pathologically diagnosed with a facial benign tumor (e.g., melanocytic nevus, sebaceous cyst, seborrheic keratosis, etc.) and having undergone standard surgical treatment. * Voluntary participation in this study with written informed consent obtained. * Commitment to comply with all study protocols and to complete all follow-up visits and data collection procedures. Exclusion Criteria: * Clinically or postoperatively diagnosed with a facial malignant tumor. * Wounds requiring staged excision or planned for secondary intention healing. * Surgical site located on or adjacent to the mucosal surface. * Known history of allergy to any medications or dressings to be used during or after surgery. * Presence of systemic diseases that significantly impair wound healing (e.g., poorly controlled diabetes, immunodeficiency disorders, active infections). * Current use of medications affecting wound healing or scar formation (e.g., long-term systemic corticosteroids, immunosuppressants). * Pregnancy or lactation. * Refusal to provide written informed consent, or anticipated inability to comply with study follow-up and data collection. * Concurrent participation in another interventional clinical trial. * Any other condition deemed by the investigator as likely to interfere with study results or increase participant risk.
References
Publications (0)
Data not yet available